What are the indications, dosing regimens, contraindications, adverse effects, and alternative therapies for alprostadil (prostaglandin E1) in term or near‑term neonates with congenital heart defects requiring ductus arteriosus patency and in adult males with erectile dysfunction?

Alprostadil: Clinical Applications in Neonatal Cardiology and Erectile Dysfunction

Neonatal Indications

Alprostadil (prostaglandin E1) is indicated to maintain ductus arteriosus patency in neonates with ductus-dependent congenital heart disease, specifically in three clinical scenarios: lesions requiring ductal-dependent pulmonary blood flow, lesions requiring ductal-dependent systemic blood flow, and admixture lesions requiring improved intracardiac mixing. 1

Specific Cardiac Lesions Requiring Alprostadil

Ductal-dependent pulmonary blood flow:

• Pulmonary atresia (with or without ventricular septal defect) 1, 2
• Tricuspid atresia 1, 3
• Critical pulmonary stenosis 1, 3
• Ebstein's anomaly with severe obstruction 3

Ductal-dependent systemic blood flow:

• Hypoplastic left heart syndrome 1
• Critical aortic stenosis 4
• Coarctation of the aorta 1, 3
• Interrupted aortic arch 1, 3

Admixture lesions:

• Transposition of the great arteries (to improve mixing) 1, 3
• Transposition with intact ventricular septum (to improve left ventricular volumes) 3

Neonatal Dosing Regimen

Initial dose: 0.05 mcg/kg/min, rapidly reduced to maintenance dose of 0.01 mcg/kg/min or lower once clinical effect is achieved. 3, 4, 5 The ACC/AHA guidelines specifically recommend prostaglandin E1 administration while withholding oxygen in neonates with systemic outflow obstruction, as oxygen can constrict the ductus and reduce systemic output. 1

Very low-dose regimens (<0.01 mcg/kg/min) are equally effective as standard low-dose regimens (≥0.01 mcg/kg/min) with potentially fewer adverse effects. 2 A 2024 study demonstrated 88% effectiveness with very low-dose alprostadil, with reduced incidence of apnea and pyrexia compared to standard low-dose therapy. 2

Starting doses as low as 0.01 mcg/kg/min may be preferred when treatment is initiated before transfer to a pediatric cardiac center. 5

Duration and Efficacy in Neonates

• Alprostadil can be used effectively for up to 13 days with sustained benefit 3
• Treatment duration in clinical studies has ranged from 1 hour to 408 hours 5
• Efficacy rates range from 76.5% to 95% across multiple studies 3, 5, 6
• The drug remains effective in neonates beyond the first week of life, with successful use documented up to 39-45 days of age 3, 4
• Greatest elevation in arterial oxygen saturation occurs in infants treated within the first 21 days of life, particularly within the first 7 days (average increase of 24.5 vol. O2%) 6

Neonatal Adverse Effects and Monitoring

Apnea is the most significant adverse effect, occurring in approximately 9-16% of spontaneously breathing infants. 3, 4 Close monitoring is essential, particularly for spontaneously breathing neonates. 3

Other adverse effects include:

• Hyperpyrexia 3, 5
• Hypotension 4, 5
• Seizures/jitteriness 3, 4
• Necrotizing enterocolitis (rare) 3
• Local skin reactions (rare) 3

All side effects are dose-related and reversible; serious side effects are uncommon at doses below 0.05 mcg/kg/min. 5

Clinical Monitoring Parameters in Neonates

• Arterial oxygen saturation (PaO2 and SaO2%) for cyanotic lesions 3
• Presence of lower limb pulses for coarctation/systemic outflow lesions 3
• Ductus arteriosus diameter by serial echocardiography 3, 6
• Respiratory status (apnea monitoring mandatory) 3
• Serum glucose, calcium, and hemoglobin levels (abnormalities may accompany or cause heart failure) 1

Contraindications in Neonates

Oxygen should be withheld during alprostadil therapy in neonates with systemic outflow obstruction because oxygen causes pulmonary vasodilation and systemic vasoconstriction, potentially constricting the ductus and reducing systemic cardiac output. 1

---

Adult Indications: Erectile Dysfunction

Alprostadil is FDA-approved as the only single-agent intracavernosal injection therapy for erectile dysfunction in the United States and is available in three formulations: intracavernosal injection, intraurethral suppository, and topical cream. 7, 8

Mechanism of Action

Alprostadil is a synthetic vasodilator identical to prostaglandin E1 that relaxes smooth muscles of the corpus cavernosum and increases cavernous artery diameter to produce erections. 8

Efficacy in Erectile Dysfunction

Intracavernosal injection (ICI) with alprostadil is the most effective non-surgical treatment for erectile dysfunction, with 66% of patients achieving erections adequate for intercourse and patient/partner satisfaction rates of 80-90%. 7

• Intraurethral alprostadil achieves successful intercourse in 29.5% to 78.1% of patients, with the largest study showing 64.9% success rate 8

Mandatory Initiation Protocol

The first administration of alprostadil must be performed under direct healthcare-provider supervision because syncope occurs in approximately 3% of patients and prolonged erections may develop. 7, 8

Required steps before home use:

1. In-office test dose with physician present to determine minimal effective dose 7, 8
2. Monitoring for acute complications, particularly prolonged erection 7
3. Demonstration of correct intracavernous injection technique to the patient 7
4. Education on dose adjustment within predefined limits 7
5. Establishment of emergency plan for prolonged erections 7

Dosing and Administration Technique

Alprostadil monotherapy is the preferred initial ICI agent; trimix (papaverine + phentolamine + alprostadil) requires compounding pharmacy but may improve efficacy or reduce side effects. 7

Standard trimix formulation: phentolamine 1 mg + papaverine 5-20 mg + alprostadil 2.5-10 µg 7

Injection technique requirements:

• Inject in the lateral aspect of the proximal third of the penis, avoiding visible veins 7
• Alternate injection sites between left and right sides to minimize tissue trauma 7
• Do not administer more than once within a 24-hour period 7
• Ongoing training and periodic follow-up decrease improper injections and improve success 7

Priapism Management Protocol

Priapism is defined as an erection lasting longer than 4 hours and requires immediate intervention to prevent corporal tissue damage. 7

Critical safety requirements:

• Prescribing physicians must educate patients about prolonged erection risk and establish an urgent treatment plan before initiating therapy 7, 8
• Patients must report any erection lasting ≥4 hours immediately 7, 8
• Delayed treatment causes irreversible corporal fibrosis and permanent erectile dysfunction 7
• Early intracavernosal phenylephrine administration within 4 hours typically reverses the condition 7
• Men treated with alprostadil alone are less prone to progress to ischemic priapism compared to those treated with papaverine and phentolamine 8

Contraindications and Cautions in Adults

Absolute contraindications:

• Patients who cannot recognize or respond to priapism warning signs 7
• Absence of an established emergency plan for prolonged erections 7
• Inadequate manual dexterity or visual acuity for self-administration 7

Relative cautions:

• Bleeding disorders (alprostadil inhibits platelet aggregation; use with caution) 7
• Recent cerebrovascular accident or myocardial infarction (requires careful clinical consideration) 7
• Pre-existing lower-limb varicosities (may cause discomfort with intraurethral formulation) 7

Advantages Over Oral Therapies

Alprostadil has few contraindications or drug interactions relative to oral phosphodiesterase-5 inhibitors and can be employed in patients with vascular disease where PDE5 inhibitors are contraindicated. 7

Adverse Effects in Adults

• Hypotension (approximately 3% after first dose) 7
• Priapism/prolonged erection (requires immediate treatment) 7
• Penile pain or discomfort 7
• Local injection site reactions 7

Follow-Up Requirements

Regular follow-up with careful penile examination at treatment start and at 3-month intervals is recommended to identify penile changes. 7 Review between 4 weeks and 6 months allows for treatment modification or cessation. 7

---

Alternative Therapies

For Neonatal Ductus-Dependent Lesions

Ductal stenting may provide acceptable short-term palliation in select cyanotic newborns, particularly those with critical pulmonary stenosis or pulmonary atresia with intact ventricular septum after RV outflow tract dilation. 1

Ductal stenting criteria for optimal risk-benefit ratio:

• Relatively straight ductus (no more than 1-2 bends) 1
• Requirement for reliable palliation for no more than 3-6 months 1
• Stent must cover entire ductus from pulmonary artery to aortic end to avoid early restenosis 1

Limitations of ductal stenting:

• Early restenosis is common (freedom from reintervention: 89% at 6 months, 55% at 12 months) 1
• Less reliable than surgical aortopulmonary shunt 1
• Technically challenging in tortuous ducts (≥2 turns) 1
• Prostaglandin E1 infusion may need to be stopped several hours before the procedure to provide a stable site for stent anchoring 1

Surgical alternatives:

• Systemic-to-pulmonary artery shunt (more reliable long-term palliation than ductal stenting) 1

For Erectile Dysfunction

Oral phosphodiesterase-5 inhibitors are typically first-line therapy but have more contraindications and drug interactions than alprostadil. 7

Vacuum erection devices are contraindicated in individuals with bleeding tendencies. 7

Combination therapy (bimix or trimix) using papaverine, phentolamine, alprostadil, and/or atropine can increase efficacy or reduce side effects compared to alprostadil monotherapy. 7

---

Special Considerations

Fertility and Alprostadil Use

The 2025 European Association of Urology guidelines do not list any fertility warnings or required discontinuation for topical alprostadil when men are attempting conception, indicating the medication is considered safe in this context. 9

• Alprostadil can be used without fertility-related restrictions for men actively trying to conceive 9
• No discontinuation period is advised for alprostadil, unlike gonadotoxic medications such as cyclophosphamide (3 months), methotrexate (1-3 months), or mycophenolate (1.5 months) 9
• Standard fertility work-up (semen analysis, morning testosterone, FSH levels) is advised for men with erectile dysfunction planning pregnancy 9
• Modifiable risk factors (smoking, excess body weight, physical inactivity) have greater impact on both erectile function and fertility than adjustments to erectile dysfunction medication 9

Perioperative Management

ESC/ESA guidelines do not recommend holding alprostadil or other erectile dysfunction therapies prior to non-cardiac surgery. 8 Alprostadil should be resumed when the patient has recovered sufficiently to engage in sexual activity postoperatively. 8